에리스로포이에틴 의약품 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Erythropoietin Drugs Market size is expected to reach USD 24.44 Billion in 2034 from USD 16.05 Billion (2025) growing at a CAGR of 4.78% during 2026-2034.

The Global Erythropoietin Drugs Market is expanding due to the increasing prevalence of chronic kidney disease and anemia. Erythropoietin drugs stimulate red blood cell production, making them essential in managing anemia related to renal disorders and chemotherapy. Rising aging populations and growing cancer incidence further drive demand. Improved access to biologic therapies also supports market growth.

Major drivers include advancements in biosimilar development and cost-effective treatment options. Growing awareness about anemia management and improved diagnostic capabilities enhance early intervention. Expanding dialysis centers and oncology treatment facilities worldwide further boost demand. Favorable reimbursement policies in developed countries also contribute to sustained market expansion.

Future prospects are promising with ongoing research in long-acting formulations and improved delivery systems. Emerging markets are expected to witness strong growth due to expanding healthcare access. Technological innovations and increasing focus on patient-centric treatment approaches will further strengthen the market. As chronic disease management gains importance, erythropoietin drugs will remain critical in anemia treatment.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Biosimilars
• First-Generation Formulation
• Second-Generation Formulation

By Drug Class

• Epoetin-Alfa
• Epoetin-Beta
• Darbepoetin-Alfa
• Other Drug Classes

By Application

• Cancer
• Renal Diseases
• Neurology
• Hematology
• Other Applications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

COMPANIES PROFILED

• AstraZeneca PLC, Amgen Inc, Biocon Limited, Celltrion Inc, Dr Reddys Laboratories Ltd, F HoffmannLa Roche Ltd, Intas Pharmaceuticals Ltd, Johnson Johnson, Kyowa Kirin Co Ltd, LG Chem Ltd, Novartis AG
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ERYTHROPOIETIN DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Biosimilars Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. First-Generation Formulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Second-Generation Formulation Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ERYTHROPOIETIN DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Epoetin-Alfa Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Epoetin-Beta Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Darbepoetin-Alfa Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ERYTHROPOIETIN DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Renal Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Other Applications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ERYTHROPOIETIN DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ERYTHROPOIETIN DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Type
  • 8.2.2 By Drug Class
  • 8.2.3 By Application
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Type
  • 8.3.2 By Drug Class
  • 8.3.3 By Application
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Type
  • 8.4.2 By Drug Class
  • 8.4.3 By Application
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Type
  • 8.5.2 By Drug Class
  • 8.5.3 By Application
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Type
  • 8.6.2 By Drug Class
  • 8.6.3 By Application
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL ERYTHROPOIETIN DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca PLC
  • 10.2.2 Amgen Inc
  • 10.2.3 Biocon Limited
  • 10.2.4 Celltrion Inc
  • 10.2.5 Dr. Reddy'S Laboratories Ltd
  • 10.2.6 F. Hoffmann-La Roche Ltd
  • 10.2.7 Intas Pharmaceuticals Ltd
  • 10.2.8 Johnson & Johnson
  • 10.2.9 Kyowa Kirin Co. Ltd
  • 10.2.10 LG Chem Ltd
  • 10.2.11 Novartis AG